News
Coya Therapeutics sees success in early COYA-302 FTD trial, aims for Phase 2b in H2 2025 and ALS filing in Q2 2025. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback